Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 15, 2005 - Issue 1
Submit an article Journal homepage
78
Views
7
CrossRef citations to date
0
Altmetric
Review

Profiles of COX-2 inhibitors: present and future

Shin Chung Drug Discovery, AmorePacific R&D Center, 314-1 Bora-ri, Giheung-eup, Yongin, Gyeonggi-do 449-729, Republic of Korea. [email protected]
,
Kyung Min Lim Drug Discovery, AmorePacific R&D Center, 314-1 Bora-ri, Giheung-eup, Yongin, Gyeonggi-do 449-729, Republic of Korea. [email protected]
&
Song Seok Shin Drug Discovery, AmorePacific R&D Center, 314-1 Bora-ri, Giheung-eup, Yongin, Gyeonggi-do 449-729, Republic of Korea. [email protected]
Pages 9-32 | Published online: 22 Apr 2005

Bibliography

  • DE LEVAL X, JULEMONT F, DELARGE J, SANNA V, PIROTTE B, DOGNE J-M: Advances in the field of COX-2 inhibition. Expert Opin. Ther. Patents (2002) 12(7):969–968.
  • •A good review covering classes of selective COX-2 inhibitors disclosed prior to 2002.
  • SIMMONS DL, BOTTING RM, HLA T: Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. PharmacoL Rev. (2004) 56(3):387–437.
  • •An extensive review article on COX covering biology, history and clinical profiles.
  • FITZGERALD GA: COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. (2003) 2(11):879–890.
  • ••A good review dealing with COX-2 inhibitors from clinical perspectives.
  • VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. (1971) 231(25):232–235.
  • FU J-Y, MASFERRER JL, SEIBERT K, RAZ A, NEEDLEMAN P: The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. (1990) 265(28):16737–16740.
  • DEWITT DL, SMITH WL: Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from complementary DNA sequence. Proc. Natl Acad. Sci. USA (1988) 85(5):1412–1416.
  • HABENICHT AJ, GEORIG M et al.: Human platelet-derived growth factor stimulates prostaglandin synthesis by activation and rapid de novo synthesis of cyclooxygenase. j Clin. Invest. (1985) 75(4):1381–1387.
  • HAN J-W, SADOWSKI H, YOUNG DA: Persistent induction of cyclooxygenase in p60v-src transfromed 3T3 fibroblasts. Proc. Natl Acad. Sci. USA (1990) 87(9):3373–3377.
  • SIMMONS DL, LEVY DB, YANNONI Y, ERIKSON RL: Identification of a phorbol ester-repressible v-src-inducible gene. Proc. Natl Acad. Sci. USA (1989) 86(4):1178–1182.
  • O'BANION MK, SADOWSKI HB, WINN V, YOUNG DA: A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. Biol. Chem. (1991) 266(34):23261–23267.
  • FLETCHER BS, KUJUBU DA, PERRIN DM, HERSHMAN HR: Structure of the mitogen-inducible TIS10 gene and demonstrations that the TIS10-encoded protein is a functional prostaglandin G/H synthase. j Biol. Chem. (1992) 267(7):4388–4344.
  • HLA T, NEILSON K: Human cyclooxygenase-2 cDNA. Proc. Natl Acad. Sci. USA (1992) 89(16):7384–7388.
  • Cl-JAN TA: Nonsteroidal anti- inflammatory drugs, apoptosis, and colon cancer chemoprevention. Lancet Oncol. (2002) 3(3):166–174.
  • LYNCH PM: COX-2 inhibition in clinical cancer prevention. Oncology (2001) 15(355):21–26.
  • INT VELD BA, RUITENBERG A. HOFMAN A et al.: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl. J. Med. (2001) 345(21):1515–1521.
  • SAWAOKA H, TSUJI S et al.: Expression of cyclooxygenase-2 gene in gastric epithelium. J. Clin. Gastroenterol (1997) 25(S1):5105–S110.
  • GRETZER B: Selective cyclo-oxygenase 2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br. J. Pharmacol (1998) 123(5):927–935.
  • WALLACE JL, RENDER BK, MCKIGHT W, BAK A: Selective inhibition of cyclooxygenase-2. Are they really effective, selective, and GI safe? Clin. Gastroenterol (1998) 27(S1):S28–S34.
  • SILVERSTEIN FE, FAICH G et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized clinical trial. JAMA (2000) 284(X):1247–1255.
  • •A report on the GI safety profiles of celecoxib.
  • HRACHOVEC JB, MORA M, WRIGHT JM et aL: Reporting of 6-month versus 12-month data in a clinical trial of celecoxib. JAMA (2001) 286(19):2398–2400.
  • BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N EngL J. Med. (2000) 343(20:1520–1528.
  • •A report on the GI safety profiles of rofecoxib.
  • SCHNITZER TJ, BURMESTER GR et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet (2004) 364(9435):665–674.
  • •A report on the GI safety profiles of lumiracoxib.
  • TAYLOR DW, BARNETT HJ et aL: Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomized controlled trial. Lancet (1999) 353(9170:2179–2184.
  • FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N EngL J. Med. (2001) 345(5):433–442.
  • DEGNER F, SIGMUND R, ZEIDLER H: Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin. Therap. (2000) 22(4):400–410.
  • •A report on the GI safety profiles of meloxicam.
  • MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286(8):954–959.
  • ••The first article to raise the cardiotoxicityissue of selective COX-2 inhibitors.
  • KONSTAM MA, WEIR MR, REICIN A et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 104(19):2280–2288.
  • FARKOUH ME, KIRSHNER H, HARRINGTON RA et aL: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: radomised controlled trial. Lancet (2004) 364(9435):675–684.
  • ••A report on the CV safety profiles oflumiracoxib.
  • CURTIS SP, NG J, YU Q et aL: Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin. Therapeut. (2004) 26(1):70–83.
  • COLLINS R, PETO R et aL: Blood pressure, stroke, and coronary artery heart disease. Part 2, short term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet (1990) 335(8693):827–838.
  • CHENG Y, AUSTIN SC, ROCCA B et aL: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 296(5567):539–541.
  • •An article addressing the potential thrombosis risk by selective inhibition of COX-2.
  • BELTON 0, FITZGERALD D: Cyclooxygenase-2 inhibitors and atherosclerosis. J. Am. Coll. CardioL (2003) 41(10):1820–1822.
  • WEBER A, CASINI A, HEINE A et aL: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47(3):550–557.
  • •An article on the CA inhibition by celecoxib and valdecoxib.
  • CENTER FOR DRUG EVALUATION AND RES., FDA: Pharmacology Review. Application Number: NDA 20–998 (Celecxoib).
  • CENTER FOR DRUG EVALUATION & RES., FDA: Pharmacology Review. Application Number: NDA 21–341 (Valdecoxib).
  • IKEDA Y, UMEMURA K, KONDO K et al.: Pharmacokinetics and safety of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Br. J. Clin. Pharmacol. (2002) 54(5):453–462.
  • RIENDEAU D, PERCIVAL MD, BRIDEAU C et aL: Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2: j Pharmacol. Exp. Therapeut. (2001) 296(2):558–566.
  • MCADAM BF, CATELLA-LAWSON I et al.: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA (1999) 96(1):272–277.
  • CATELLA-LAWSON F, MCADAM B, MORRISON BW et aL: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. j Pharmacol. Exp. Therapeut. (1999) 289(2):735–741.
  • BRATER DC: Renal effects of cyclooxygenase-2-selective inhibitors. J. Pain Symptom Management (2002) 23(451):515–520.
  • MELK A, SCHMIDT BM, TAKEUCHI 0 et aL: Expression of MIN" and other cell cycle and senescence associated genes in aging human kidneys. Kidney Int. (2004) 65(2):510–520.
  • ROSSAT J, MILLARD M, NUSSBERGER J et aL: Renal effects of cyclooxygenase-2 inhibition on renal function in normotensive salt-depleted subjects. Clin. PharmacoL Therapeut. (1999) 66(1):76–84.
  • WEAVER A, ALDERMAN M, SPERLING R: Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis. Am. J. CardioL (2003) 91(10):1291–92.
  • BRATER DC: Renal effects of COX-2-selective inhibitors. Am. J. NephroL (2001) 21(1):1–15.
  • MAREN TH: Carbonic anhydrase: chemistry, physiology and inhibition. PhysioL Rev. (1967) 47(4):595–781.
  • SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents (2000) 10(5):575–600.
  • KEEBLE JE, MOORE PK: Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal and related nitric oxide-donating drugs. Br. J. Pharmacol. (2002) 137 (3): 295–310.
  • LANA A, BAJADOR E, SERRANO P et aL: Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N EngL J. Med. (2000) 343(12):834–839.
  • RANATUNGE RR, AUGUSTYNIAK M, BANDARAGE UK et aL: Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. J. Med. Chem. (2004) 47(9):2180–2193.
  • FIORUCCI S, MELT R, BUCCI M, CIRINO G: Dual inhibitors of cyclooxygenase and 5-lipooxygenase. A new avenue in anti-inflammatory therapy? Biochem. PharmacoL (2001) 62(11):1433–1438.
  • GAMBARO G: Strategies to safely interfere with prostanoid activity while avoiding adverse renal effects: could COX-2 and COX-LOX dual inhibition be the answer? NephroL Dial. Transplant. (2002) 17(7):1159–1162.
  • BIAS P, BUCHNER A et al.: The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers from a randomized, controlled trial. Am. J. Gastroenterol. (2004) 99(4):611–618.
  • BOILEAU C, MARTEL-PELLETIER J, JOUZEAU J-Y et al.: Licofelone (ML-3000), a dual inhibitor of 5-lipooxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. J. Rheumatol. (2002) 29(7):1446–1453.
  • GOLDENBERG MM: Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Therapeut. (1999) 21(9):1497–1513.
  • CANNON GW, CALDWELL JR, HOLT P et al.: Rofecoxib, a specific inhibitor of cyclooxygenase-2, with clinical efficacy comparable with that diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum. (2000) 43(5):978–987.
  • KUNE GA, KUNE S, WATSON LF: Colorectal cancer risk, chronic illness, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. (1988) 48(15):4399–4404.
  • ROSENBERG L, PALMER JR, ZAUNER AG et al.: A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of the large-bowel disease. J. Nail. Cancer Inst. (1991) 83(5):355–358.
  • GREENBERG ER, BARON JA, FREEMAN Jr DH et al.: Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Group. J. NatL Cancer Inst. (1993) 85(11):912–916.
  • SPAGNESI MT, TONELLI F, DOLARA P et al.: Rectal proliferation and polyp occurrence in patients with adenomatous polyposis after sulindac treatment. Gastroenterology (1994) 106(2):362–366.
  • KARGMAN S, O'Neill, VICKERS PJ et al.: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. (1995) 55(12):2556–2559.
  • GUSTAFSON-SVARD C, LILJA I et al.: Cyclooxygenase-1 and cyclooxygenase-2 gene expression in colorectal adenocarcinomas and azoxymethane induced colonic tumors in rats. Gut (1996) 38(1):79–84.
  • OSHIMA M, DINCHUK JE, KARGMAN SL et al.: Suppression of intestinal polyposis in APC-E716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell (1996) 87(5):803–809.
  • KISMET K, AKAY MT, ABBASOGLU 0, ERCAN A: Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Det. Prey. (2004) 28(2):127–142.
  • ••An extensive review on the anticancereffects of COX-2 inhibitors.
  • SUBBARAIVIAIAH K, DANNENBERG AJ: Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends PharmacoL Sci. (2003) 24(2):96–102.
  • ••An excellent review discussing theantitumor effect by COX-2 inhibitors at molecular level.
  • DUBOIS RN, RADHIKA A, REDDY BS et al.: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology (1996) 110(4):1259–62.
  • WILLIAMS CS, LUONGO C, RADHIKA A et al.: Elevated cyclooxygenase-2 levels in MM mouse adenomas. Gastroenterology (1996) 111(4):1134–1140.
  • FUJITA T, MATSUI M, TAKAKU K et aL: Size- and invasion-dependent increase in cyclooxygenase-2 levels in human colorectal carcinomas. Cancer Res. (1998) 58(21):4823–4826.
  • KAWAMORI T, RAO CV, SEIBERT K et al.: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. (1998) 58(3):409–412.
  • STEINBACH G, LYNCH PM, PHILLIPS RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. J. Med. (2000); 342(26):1946–52.
  • •A report on the anticancer activity of celecoxib in FAR
  • WET M, MORIMURA K, WANIBUCHI H et al.: Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Cancer Lett. (2003) 202(1):11–16.
  • THUN MJ, NAMBOODIRI MM, HEATH CW Jr: Aspirin use and reduced risk of fatal colon cancer. N EngL J. Med. (1991) 325(23):1593–6.
  • PAGANINI-HILL A, CHAO A. ROSS RK, HENDERSON BE: Aspirin use and chronic diseases: a cohort study of the elderly. BMJ (1989) 299(6710):1247–50.
  • EGAN KM, STAMPFER MJ, GIOVANNUCCI E et al.: Prospective study of regular aspirin use and the risk of the breast cancer. J. Natl. Cancer Inst. (1996) 88(14):988–93.
  • ROSENBERG L: Nonsteroidal anti-inflammatory drugs and cancer. Prey. Med. (1995) 24(2):107–109.
  • SCHREINEMACHERS DM, EVERSON RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology (1994) 5(2):138–46.
  • HARRIS RE, NAMBOODIRI KK, FARRAR WB: Non-steroidal antiinflammatory drugs and breast cancer. Epidemiology (1996) 7(2):203–5.
  • HWANG D, SCOLLARD, BYRNE J, LEVINE E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer./ Natl. Cancer Inst. (1998) 90(6):455–60.
  • LIU CH, CHANG SH et aL: Over-expression of cyclooxygenase (COX)-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. (2001) 276(21):18563–18569.
  • ZHAO Y, AGARWAL VR, MENDELSON CR, SIMPSON ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP leading to activation of promoter II of the CYP II (aromatase) gene. Endocrinology (1996) 137(2):5739–5742.
  • BRUEGGEMEIER RW, QUINN AL, PARRETT ML et al.: Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens: Cancer Lett. (1999) 140(1-2):27–35.
  • TERRY MB, GAMMON MD et al.: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 291(20):2433–2430.
  • RODRIGUEZ G, GONZALEZ -PEREZ A: Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br. J. Cancer (2004) 91(3):525–529.
  • HARRIS RE, ALSHAFIE GA, ABOU-ISSA H, SEIBERT K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. (2000) 60(8):2101–3.
  • ABOU-ISSA HM, ALSHAFIE GA, SEIBERT K et al.: Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res. (2001) 21(5):3425–3432.
  • KUBATKA P, AHLERS I, AHLERSOVA E et al.: Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett. (2003) 202(2):131–136.
  • NAKATSUGI S, OHTA T, KAWAMORI T et al.: Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-pyridine (PhIP)-induced mammary gland carcinogenesis in rats. lap. J. Cancer Res. (2000) 91(9):886–892.
  • SAWAOKA H, KAWANO S, TSUJI S et al.: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol. (1998) 274(6 Pt.1):G1061–G1067.
  • ZIMMERMANN KC, SARBIA M, WEBER AA et al.: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. (1999) 59(1):198–204.
  • CHAN G, BOYLE JO, YANG EK et aL: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. (1999) 59(5):991–994.
  • THUN MJ, CALLE EE, FLANDERS WD et al.: Aspirin use and risk of fatal cancer. Cancer Res. (1993) 53(6):1322–1327.
  • FUNKHOUSER EM, SHARP GB: Aspirin and reduced risk of esophageal carcinoma. Cancer (1995) 76(7):1116–1119.
  • SHIOTANI H, DENDA A et al.: Increased expression of cyclooxygenase-2 protein and 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res. (2001) 61 (4): 1451–1456.
  • RIOUX N, CASTONGUAY A: Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. (1998) 58(23):5354–5360.
  • GRUBBS CJ, LUBET RA et al.: Celecoxib inhibits N-butyl-N-(4-hydroxybuty1)-nitrosoamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. (2000) 60(20):5599–5602.
  • TIANO HF, LOFTIN CD, AKUNDA J et al.: Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. (2002) 62(12) :3395–3401.
  • FISCHER SM, LO HH, GORDEN GB et al.: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. MoL Carcinogenenesis (1999) 25(4):231–40.
  • PENTLAND AP, SCHOGGINS JW, SCOTT GA et al.: Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis (1999) 20(10):1939–44.
  • YOSHIMURA R, SANO H, MASUDA C et aL: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer (2000) 89(3):589–596.
  • DERKSEN E, WALLEN E, PRUTHI R: A Phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy (XRT) or radical prostatetectomy (RP). J. Am. Coll. Surgeons (2004) 199(351):100–101.
  • SUBBARAMAIAH K, NORTON L, GERALD W, DANNENBERG A: Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. j Biol. Chem. (2002) 277(21):18649–18657.
  • SUBBARAMAIAH K, ALTORKI N, CHUNG WJ et al.: Inhibition of cyclooxygenase-2 gene expression by p53. Biol. Chem. (1999) 274(10:10911–10915.
  • RISTIMAKI A. SIVULA A, LUNDIN J et al.: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. (2002) 62(3):632–635.
  • SHENG H, SHAO J, DIXON DA et al.: Transforming growth factor-al enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. (2000) 275(9):6628–6635.
  • DIXON DA, TOLLEY ND, KING PH et al.: Altered expression of mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. (2001) 108(3):1657–1665.
  • INIGUEZ MA, RODRIGUEZ A, VOLPERT OV et al.: Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends MoL Med. (2003) 9(2):73–78.
  • •A good review dealing with the anti-angiogenic activity of COX-2 inhibitors.
  • TSUJII M, KAWANO S, TSUJI S et al.: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 93(5):705–16.
  • WILLIAMS CS, TSUJII M, REESE J et al.: Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. (2000) 105(1 0:1589–1594.
  • EIBL G, BRUEMMER D, OKADA Y et al.: PGE, is generated by specific COX-2 activity and increases VEGF production in COX-2 expressing human pancreatic cancer cells. Biochem. Biophys. Res. Comm. (2003) 306(4):887–897.
  • CSIKI I, GONZALEZ A, CARBONE DP et al.: Cyclooxygenase-2 (COX-2) inhibition in advanced non-small cell lung cancer (NSCLC): preliminary results of a Phase II trial (TH0-0054). Lung Cancer (2003) 41(52):5182.
  • O'DONOGHUE GT, ROCHE -NAGLE G, CONNOLLY EM et al.: Selective COX-2 inhibition of attenuates the perioperative increase of the tumor enhancing pro-angiogenic cytokine VEGF in human breast cancer patients. J. Surgical Res. (2003) 114(2):243.
  • HET-C, CHAN TA, VOGELSTEIN B, KINZLER KW: PPAR, is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell (1999) 99(3):335–345.
  • RUBINFELD B, SOUZA B et al.: Association of the APC gene product with 13-catenin. Science (1993) 262(5140):1731–1734.
  • SULK, VOGELSTEIN B, KINZLER KW: Association of the APC tumor suppressor protein with catenins. Science (1993) 262(5140):1734–1737.
  • BOON EM, KELLER JJ et al: Sulindac targets nuclear a-catenin accumulation and Wnt signaling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br. J. Cancer (2004) 90(1):224–229.
  • TOMOZAWA S, NAGAWA H, TSUNO N et al.: Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer (1999) 81(8):1274–79.
  • MASFERRER JL, LEAHY KM, KOKI AT et al.: Anti-angiogenic and anti-tumor activities of cyclooxygenase-2 inhibitors. Cancer Res. (2000); 60(5):1306–11.
  • PATEL VA, DUNN MJ, SOROKIN A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. j Biol. Chem. (2002) 277(41):38915–38920.
  • MAIER TJ, SCHILLING K, SCHMIDT R et al.: Cyclooxygenase-2 (COX-2)-dependent and -independent anti-carcinogenic effects of celecoxib in human colon carcinoma cells: Biochem. Pharmacol (2004) 67(8):1469–1478.
  • HSU A-L, CHING T-T, WANG D-S et aL: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking AKT activation in human prostate cancer cells independently of bc1-2. j Biol. Chem. (2000) 275(15):11397–11403.
  • HIDA T, KOZAKI K-I, MURAMATSU H et al.: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell (NSCLC) lines. Clin. Cancer Res. (2000) 6(5):2006–2011.
  • MUNKARAH AR, BAUMANN MR, DEPPE G et al.: Effect of prostaglandin E, on proliferation and apoptosis of epithelial ovarian cancer cells. J. Soc. Gynecol Invest. (2002) 9(3):168–73.
  • MUNKARAH AR, GENHAI Z, MORRIS R et al: Inhibition of paditaxel-induced apoptosis by specific by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol (2003) 88(3):429–433.
  • LASKIN JJ, SANDLER AB: The importance of the eicosanoid pathway in lung cancer. Lung Cancer (2003) 41(S1): S73–S79.
  • COFFEY RJ, HAWKEY CJ, DAMSTRUP Let al.: Epidermal frowth factor receptor activation induces nuclear targeting of cyclooxygenase 2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc. Natl Acad. Sci. USA (1997) 94(2):657–652.
  • ROSATO FE, DICKER A et ed.: Combining the epidermal growth factor receptor tyrosine kinase inhibitor, ZD1839, with a selective cyclooxygenase-2 (COX-2) inhibitor, 5C236, causes a cooperative antitumor effect in breast cancer cells derived from HER2/neu mice. J. Surg. Res. (2003) 14(2):274.
  • LEE JC, KELLEY MC: Combined inhibition of epidermal growth factor receptor and COX-2 enhances growth inhibition in lung cancer cell lines. Lung Cancer (2003) 41(52):166.
  • MILAS L, HANSON WR: Eicosanoids and radiation. Eur. J. Cancer (1995) 31A(10):1580–1585.
  • NAKATA E, MASON KA, HUNTER N et al.: Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int. J. Radiation Oncol Biol. Phys. (2004) 58(2):369–375.
  • CHOY H, MILAS L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J. Natl Cancer Inst. (2003) 95(19):1440–1452.
  • DADIS TW, O'NEAL JM et al: Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. (2004) 64(1):279–285.
  • CHOW LW WONG JL, TOI M: Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J. Steroid Biochem. Mol Biol. (2003) 86(3-5):443–447.
  • VANHOEFER U, ROUGIER P, BORNER M et al.: Irinotecan in combination with new agents. EJC Suppl (2004) 2(7):14–20.
  • MALIMSTROM K, DANIELS S, KOTEY P et al.: Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in post operative dental pain: a randomized, placebo and active comparator-controlled clinical trial. Clin. Therapeut. (1999) 21(101653–1663.
  • GEIS GS: Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?J. Rheumatol (1999) 26(550:31–36.
  • MCCORMACK K, BRUNE K: Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. Drugs (1991) 41(4):533–547.
  • DELIGEOROGLOU E: Dysmenorrhea (Review). Ann. NY Acad. Sci. (2000) 900:237–244.
  • SAPER J, DAHLOF Y, SOP et al: Efficacy and safety of rofecoxib for the acute treatment of migraine: Combined results of two randomized, placebo-controlled trials. J. Pain (2004) 5(S1):564.
  • LOBO BL, COOKE SC, LANDY SH: Symptomatic pharmacotherapy of migraine. Clin. Therapeut. (1999) 21(7):1118–1130.
  • HERNANSANZ MAC, ROY RS, ORGAZ AC et al.: Migraine treatment patterns and patient satisfaction with prior therapy: A substudy of a multicenter trial of rizatriptan effectiveness. Clin. Therapeut. (2003) 25(7):2053–2069.
  • KRYMCHANTOWSKI AV, BIGAL ME: Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol (2004) 4(1):10.
  • NACHEMSON AL: Newest knowledge of low back pain: a critical look. Clin. Orthoped. Related Res. (1992) 279:8–20.
  • KATZ N, RODGERS D, KRUPA D, REICIN A: Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials. Curr. Med. Res. Opin. (2004) 20(5):651–658.
  • BIRBARA CA, PUOPOLO AD, MUNOZ DR: Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inihibitor: Improvement in pain and disability - A randomized, placebo-controlled, 3-month trial. J. Pain. (2003) 4(6):307–315.
  • REUBEN SS, BHOPATKAR S, MACIOLEK H et al.: The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth. Analg. (2002) 94(1):55–59.
  • MERCADANTE S: The use of anti-inflammatory drugs in cancer pain. Cancer Treat. Rev. (2001) 27(1):51–61.
  • •A review article on NSAIDs in cancer pain.
  • KANIS JA, MCCLOSKEY EV et al: Rationale for the use of bisphosphonates in bone metastasis. Bone (1991) 12(S1):S13–S18.
  • ALYSON F, MEDHURST S, COURADE J-P et al: Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain (2004) 107(1):33–40.
  • SABINO MA, GHILARDI JR, JONGEN JL et al.: Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res. (2002) 62(24):7343–7349.
  • LIM GP, YANG F, CHU T et al: Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. (2000) 20(15):5709–5714.
  • WEGGEN S, ERIKSEN JL, DAS P et al: A subset of NSAIDs lower amyloidogenic Aa42 independently of cyclooxygenase activity. Nature (2001) 414(6860):212–216.
  • GASPARINI L, RUSCONI L et Modulation of a-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J. Neurochem. (2004) 88(2):337–348.
  • SCALI C, GIOVANNI MG, BELLUCI PA et al.: The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience (2003) 117(4):909–919.
  • AISEN PS, SCHAFER KA, GRUNDMAN M et al.: Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression. JAMA (2003) 289(21):2819–2826.
  • ZANDI PP, ANTHONY JC, HAYDEN KM et al.: Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology (2002) 59(6):880–886.
  • MARTIN BK, MEINERT CL, BREITNER JCS et al: Double placebo design in a prevention trial for Alzheimer's disease. Control. Clin. Trials (2002) 23(1):93–99.
  • LI J, DEMELLO KML et aL: Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethy1-5-phenyl-pyrazol-1-y1)-5-methansulfonyl-pyridine. Bioorg-. Med. Chem. Lett. (2004) 14(1):95–98.
  • RANATUNGE RR, GARVEY DS et aL: Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of a novel bicyclic pyrazoles. Bioorg-. Med. Chem. (2004) 12(0:1357–1366.
  • SINGH SK, VOBBALAREDDY S et al.: Methansulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg-. Med. Chem. Lett. (2004) 14(7):1683–1688.
  • CATURLA F, JIMENEZ J-M, GODESSART N et al.: Synthesis and biological evaluation of 2-phenylpyran-4-ones: A new class of orally active cyclooxygenase-2 inhibitors. J. Med. Chem. (2004) 47(15):3874–3886.
  • J00 YH, KIM JK, KANG S-H et al: 2,3-Diarylpyran-4-ones: a new series of selective cyclooxygenase-2 inhibitors. Bioorg-. Med. Chem. Lett. (2004) 14(9):2195–2198.
  • SINGH SK, SAIBABA V, RAVIKUMAR V et al.: Synthesis and biological evaluation of 2,3-diarylpyrazines and quinoxalines as selective COX-2 inhibitors. Bioorg Med. Chem. (2004) 12(8):1881–1893.
  • CAMPBELL JA, BORDUNOV V, BROKA CA et al.: Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitors. Bioorg Med. Chem. Lett. (2004) 14(18):4741–4745.
  • UDDIN JM, RAO PNP, KNAUS EE: Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med. Chem. Lett. (2004) 14(8):1953–1956.
  • PARAIVIASHIVAPPA R, KUMAR PP, RAO PV et al.: Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxzole derivatives as cyclooxygenase inhibitors. Bioorg-. Med. Chem. Lett. (2003) 13(4):657–660.
  • SCOTT G, RORDORF C, REYNOLDS C et al.: Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin . Pharmaco. (2004) 43(7):467–478.
  • KELLSTEIN D, OTT D et al: Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib, and placebo in the treatment of post-operative dental pain. Int. J. Clin. Practice (2004) 58(3):244–250.
  • WHELTON A, WHITE WB et al.: Effects of celecoxib and rofecoxib on blood pressure and edema in patients 65 years of age with systemic hypertension and osteoarthritis. Am. J. CardioL (2002) 90(9):959–963.
  • •A head-to-head comparison trial on the cardiorenal effects between celecoxib and rofecoxib.
  • CHANDRASEKHARAN NV DAI HU, ROOS KL et ell.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, strucutre, and expression. Proc. Nail. Acad. Sci. USA(2002) 99(21):13926–13931.
  • SCHWAB JM, SCHLUESENER HJ, MEYERMANN R, SERHAN CN: COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics? Prostaglandins Leukot. Essent. Fatty Acids (2003) 69(5):339–343.
  • WHELTON A, SPALDING WM, WHITE WB et al.: Rofecoxib increases cardiovascular events in arthritis patients but celecoxib and nonsteroidal anti-inflammatory drugs do not: results from a large New England health care claims database. J. Am. Coll Cardiol (2004) 43(552):415A.
  • MAMDANI M, JUURLINK DN, LEE DS et al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet (2004) 363(9423):1751–1756.
  • •A post marketing survey addressing the difference in the cardiovascular safety between celecoxib and rofecoxib.
  • MAGGOS C, SCHAEFFER S: Deconstructing the COX-2 difference. Biocentury (2004) 12(43):A13–A14.
  • MAGGOS C: Painfully slow. Biocentury (2003) 11(41):A1–A6.

Websites

  • www.fda.gov/ohrms/dockets/ac/01/briefing/3 677152_04_stats.pdf Li Q: Statistical reviewer document for the advisory committee. (July 17, 2004).
  • www.fcia.gov/cder/foi/labe1/2002/19268s1r03 7.pdf GD Searle & Co.: Patient Informaton Sheet (Cytotec: Misoprostol) (July 26, 2004).
  • www.astrazeneca.com/pressrelease/476.aspx ASTRAZENECA INT.: Press Release. (July 19, 2004).
  • www.docguide.com/news/content.nsf/news/8 525697700573E1885256DCD0075E0DF ?OpenDocument&id48DDE4A73E09A9 69852568880078C249&cOsteoarthritis &count10 Sylvester B: ACR: Licofelone offers equal efficacy with better tolerability than celecoxib for knee osteoathritis. (July 19, 2004).
  • www.loxcoxresearch.com/pr_02.asp Merckle/Euroalliance: Press Release. (July 19, 2004).
  • http://media.corporate- irmet /media_files/irol/73/73184/reports/lq 04release.pdf Merck : 1Q04 Earnings Release. (July 21, 2004).
  • www.datamonitor.com Prexige : Innovative strategies to ensure commercial gain. Datamonitor (2003).
  • www.mcw.edu/display/router.asp?docid215 7 Medical College of Wisconsin: Current clinical trials. (July 21, 2004).
  • http://www.fcia.gov/cder/drug/infopage/vioxx /vioxxgraham.pdf Graham DJ: Risk of acute myocardial infarction and sudden cardiac death in patients treated with COX-2 selective and non-selective NSAIDs. (November 8, 2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.